Innate Pharma
IPHA
9 hedge funds and large institutions have $736K invested in Innate Pharma in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.2% less ownership
Funds ownership: 0.5% → 0.29% (-0.2%)
35% less capital invested
Capital invested by funds: $1.13M → $736K (-$393K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$130K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$40.8K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$630 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
-$437K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$133K |
| 3 |
Millennium Management
New York
|
-$38.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$37.8K |
| 5 |
Morgan Stanley
New York
|
-$5.14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Optiver Holding
Amsterdam,
Netherlands
| $257K | -$437K | -142,301 | -63% |
|
|
2
Millennium Management
New York
| $155K | -$38.3K | -12,449 | -20% |
|
|
3
Morgan Stanley
New York
| $145K | -$5.14K | -1,673 | -3% |
|
|
ETC
4
Exchange Traded Concepts
Oklahoma City,
Oklahoma
| $133K | +$130K | +42,431 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $41.7K | +$40.8K | +13,281 | New |
|
|
SPIA
6
Steward Partners Investment Advisory
New York
| $1.54K | – | – | – |
|
7
Barclays
London,
United Kingdom
| $1.27K | – | – | – |
|
|
8
RhumbLine Advisers
Boston,
Massachusetts
| $643 | +$630 | +205 | New |
|
9
UBS Group
Zurich,
Switzerland
| $449 | -$3.42K | -1,113 | -88% |
|
|
10
Bank of America
Charlotte,
North Carolina
| – | -$133K | -46,749 | Closed |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$37.8K | -13,315 | Closed |
|
IPHA Hedge Fund Activity: Q2 2023 in Review
9 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2023, worth a combined $736K — down 35% from $1.13M a quarter earlier.
Fund positioning in IPHA was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 4 trimmed.
The largest buyer was Exchange Traded Concepts, opening a new position worth an estimated $130K. The largest seller was Optiver Holding, cutting an estimated $437K.
- 9 institutional investors held Innate Pharma (IPHA) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $736K of Innate Pharma stock for Q2 2023, down 35% quarter-over-quarter.
- 3 funds opened new Innate Pharma positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Innate Pharma buyer in Q2 2023 was Exchange Traded Concepts, an estimated $130K added.
- The largest Innate Pharma seller in Q2 2023 was Optiver Holding, an estimated $437K sold.
Based on aggregated 13F filings for Q2 2023.